This website is intended for a UK audience

So that we can direct you to the most appropriate information about Decapeptyl SR (triptorelin), please choose one of the following options:

I am a healthcare professional in the UK*

*This section of the website is for UK healthcare professionals only and contains promotional content regarding our medicines.

Reporting of adverse events (healthcare professionals in the UK)

Adverse events should be reported. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777

I am a patient in the UK who has been prescribed this medicine
I am a member of the general public in the UK

Reporting of side effects (patients and public in the UK)

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at http://www.mhra.gov.uk/yellowcard By reporting side effects you can help provide more information on the safety of this medicine.

TRI-UK-005698 Date of preparation: February 2024

For UK-based Healthcare Professionals only
Search

Adverse events should be reported. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard

Adverse events should also be reported to the Ipsen Medical Information Department on +44(0) 1753 627777 or pharmacovigilance.uk-ie@ipsen.com

A link to the prescribing information can be found in the header.

Implementing Decapeptyl® SR (triptorelin) 22.5 mg 6-monthly

Learn from those who have already incorporated Decapeptyl® SR 6-monthly into their prostate cancer care pathway to help facilitate the use of less frequent LHRHa injections in your practice.

 

Implementing Decapeptyl® SR 6-monthly for prostate cancer

Implementing Decapeptyl® SR 6-monthly in your practice could lead to fewer appointments with patients leading to potential cost savings for the NHS compared with more frequent LHRHa dosing.1

A Clinical Nurse Specialist’s view

___

This video is currently being updated. Please see the latest prescribing information.

___

Switching from a 1- or 3-monthly LHRHa to Decapeptyl® SR 6 monthly “releases time for other aspects of care”

Dr Jason Alcorn Clinical Nurse Specialist, Mid Yorkshire Hospitals NHS Trust, Wakefield

Clinical Nurse Specialist Dr Jason Alcorn discusses how 6-monthly dosing with Decapeptyl® SR has been implemented in his practice at the Mid Yorkshire Hospitals NHS Trust in Wakefield.

Views expressed in this video are the speaker’s own independent opinions and experiences and do not represent those of Ipsen.

Paying for Decapeptyl® SR in primary care practice

The cost of Decapeptyl® SR in primary care practice is partly reimbursed by the NHS under the Personally Administered (PA) items allowance scheme.

What are Personally Administered items?

In any GP practice the practice team will need to administer drugs or appliances, or use a diagnostic aid, as part of the medical service provided to a patient. Such items are termed Personally Administered (PA) items.2

The NHS makes special provision for this activity in general practice and has agreed to make specific payments which are payable to GP practices when such items are prescribed and administered by the practice.2

To reimburse practices for the costs of sourcing and administering PA items, the NHS pays a PA allowance, plus a dispensing fee. The PA allowance is made to cover any VAT that has been paid on the purchase of PA items.2

Decapeptyl® SR is classified a PA item

  • GP practices receive the PA allowance for purchasing and administering Decapeptyl® SR (LHRH agonists are classified as PA items)3
  • The PA allowance encompasses medicine costs, dispensing fees and a VAT allowance

Diagram has been created by Ipsen based on PA allowance guidance.

The clawback rate applied to individual GP practices is influenced by the volume of items submitted for reimbursement per month and the number of items submitted for reimbursement per individual doctor3.

Reference

  1. Cornford P, Jefferson K, Cole O, Gilbody J. Effects of initiating or switching to a six-monthly triptorelin formulation on prostate cancer patient–healthcare interactions and hospital resource use: a real-world, retrospective, non-interventional study. Oncol Ther. 2018;6:173–87.
  2. Dispensing Doctor’s Association. Module 2- Understanding PA and VAT. Available from: https://dispensingdoctor.org/ Accessed April 2023.
  3. Dispensing Doctors’ Association. Essential Dispensing Guide 2014. Available at:https://www.dispensingdoctor.org/wp-content/uploads/2014/10/DDADispensingGuide-WEB.pdf (Accessed April 2023)
Close

Contact an Ipsen Representative

Contact us

Expand

Contact

Close

Contact an Ipsen Representative

If you would like to learn more about Decapeptyl® SR (triptorelin) for your practice, please fill in your contact details. One of our team will contact you to discuss your query.
By providing your email address, you agree to receive an email response from Ipsen to your inquiry. Your email address will only be used to respond to your inquiry. The information you submit will be governed by our Privacy Policy.
Please note that this form is not for reporting of adverse events. Information on how to report an adverse event can be found here.

TRI-UK-004985
Date of prep: June 2023

Back to top